Search

everythinglearnresearchcommunity

for

Search:↓

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Scalp biopsies are crucial for diagnosing hair loss causes in cutaneous lymphoma patients.

CRET therapy affects inflammation in skin cells by changing cytokine levels and activating certain proteins.

Timely diagnosis and aggressive treatment with high-dose steroids and B-cell depletion therapies are effective for severe acute cutaneous lupus.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.

The immune system can cause permanent skin and hair whitening by attacking pigment cells.

Upadacitinib improved multiple immune-related conditions in one patient.

Mechlorethamine treatment regrew hair in mice by killing immune cells causing hair loss without harming hair follicles.

Alopecia areata involves complex immune activity, mainly Th1, with potential benefits from broader immune treatments.

Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Alopecia areata involves complex immune dysregulation, mainly driven by Th1 activity, suggesting broader treatment strategies.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Monocyte-derived dendritic cells play a key role in UVB-induced skin sensitivity and inflammation.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

The method effectively delivers vaccines through the skin without needles.

Alopecia areata involves complex immune responses, suggesting broader treatments could help.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

A man's skin condition, pemphigus vulgaris, came back after he was treated with interleukin 2 for cancer.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

BTNL2 helps protect hair follicles from immune attacks, which could aid in treating alopecia areata.